Assembly BiosciencesASMB
Recorded

Assembly Biosciences UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Ash VermaAnalyst

Good day, everybody. Welcome to UBS Biopharma Conference in London. I'm really excited to have the Assembly Bio team with me. Jason Okazaki, who's the President and CEO, Katie Kitrinos, and Anuj Gaggar. Guys, thank you so much for joining us. Really excited to know more about what's going on with Assembly Bio. Maybe it'll be helpful if you can give a little bit of a background about Assembly. You just reported third quarter earnings, initiated a trial, I guess, or your partner Gilead did that. Just help us understand the platform and give some context so that we can dive more into more specific questions after that.

Jason OkazakiPresident and CEO

Yeah, absolutely. And thanks for having us, Ash. Pleasure to be here. So yeah, so really the company's evolved over the past six years since really this team has been here from focused solely on hep B cure to broader antivirals and actually liver disease. So what you're referring to is kind of the fruition of the pipeline we've built over the past six years. So with the lead being the HSV-2 high recurrent genital herpes asset. As you noted, that's now partnered with Gilead. Gilead opted into that program based on some very positive phase I-B data last year. They control that program and just initiated the phase II, which will be head-to-head against VALTREX, which is what we'd expected to do if we were running the program. So looking forward to the progress on that.

Jason OkazakiPresident and CEO

Then we have ABI-6250, which is a small molecule oral entry inhibitor that originally we were developing for hep delta, and that study actually initiated just two weeks ago. In May, we actually announced, and we've been looking at this for the past couple years, is really cholestatic liver diseases. So given the functionality of it being an NTCP inhibitor, and we'll talk about this, I'm sure, right? It's got a great mechanistic approach to cholestatic liver diseases, specifically PBC, PSC. So we're looking forward to initiating the phase II trials for those in the first quarter of next year.

Jason OkazakiPresident and CEO

This year frames up as a really big execution year, and next year is going to be a very heavy data on year, with the second half of the year we'll have hep D data for ABI-6250, presumably the HSV-2 recurrent genital herpes data from Gilead for phase II, and then starting first half of 2028, we should have the PBC, PSC data. So pretty excited about another big milestone year next year.

Ash VermaAnalyst

Yeah. Yeah, that's great. Let's talk about that. I mean, I guess the phase II clinical trial design got outlined at this clinicaltrials.gov. If you can talk about it, what are some of the key things to focus on? It looks like two weekly doses that you're comparing in 300 patients. Then, in this type of setting, is there a right level of enrollment pace that would help selecting the right patient population for this study?

Anuj GaggarChief Medical Officer

Yeah. Thanks for asking the question.

Anuj GaggarChief Medical Officer

Yeah. The phase II study, as was posted by Gilead on clinicaltrials.gov, gave us some insight as to how they're designing it, which is much in line with how we would design a similar study.

Anuj GaggarChief Medical Officer

As you said, there's three arms. There's a low-dose arm, a high-dose arm, and a valacyclovir control arm, and it's a 12-week dosing period. What we know about the patient population they've selected, as noted there, is it's similar to the one that we had in our phase I-B studies for both ABI-5366 and ABI-1179. That patient population makes up the majority of the patients that are out there on treatment, and they are, we know from our experience, it enrolled quite rapidly, because it is a pretty open enrollment criteria there.

Anuj GaggarChief Medical Officer

We do expect, and as posted by Gilead, that they're expecting to have the trial completed by the end of next year. We think that's a reasonable pace for that kind of a study, and I think the outcomes are going to be really exciting to look at. As we would have done in our I-B, we went against placebo, and the next step for that molecule is to go against the standard of care, valacyclovir. But as you point out, one of the main advantages is not just better efficacy, but that once-weekly dosing, which is a big improvement on convenience from the daily dosing of valacyclovir.

Ash VermaAnalyst

Yeah. Yeah. When we think about the focus on the viral shedding and the tracking the lesions, if you can talk about what type of benefit compared to valacyclovir would be pretty meaningful, either on either of the endpoints.

Anuj GaggarChief Medical Officer

Yeah. These are two very interesting ways of looking at the impact of the drug. The shedding rate is a more quantitative measure that's a little easier to get data for with a smaller group of patients and power a study for that.

Anuj GaggarChief Medical Officer

Yeah. My guess is the powering of that study may be based on the shedding versus valacyclovir.

Anuj GaggarChief Medical Officer

There's good precedent from pritelivir, a previous helicase-primase inhibitor, which went head-to-head against valacyclovir and beat it on shedding. We know that ABI-1179 is more potent than pritelivir, and we predict to have a higher efficacy than pritelivir. I think from a primary endpoint, probably that shedding is going to be very important, and we expect to see positive signal there. For lesions, the longer you evaluate patients, the more likely you are to pick up lesions and find a statistical difference between two arms. It's not clear right now if the 12 weeks is going to be sufficient and the number is sufficient. We would expect directionality at least in the direction of improved lesions with 1179 versus valacyclovir.

Anuj GaggarChief Medical Officer

These molecules and the programs themselves were designed to have better efficacy than valacyclovir. We would expect to see certainly statistical significance on, let's say, the shedding endpoint and directionality probably on the lesions as well.

Ash VermaAnalyst

Got it. Does that change in any way, like in subsequent trials? Does lesion at some point need to become a primary?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day